Literature DB >> 16360395

Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy.

David Velázquez-Fernández1, Cecilia Laurell, Janos Geli, Anders Höög, Jacob Odeberg, Magnus Kjellman, Joakim Lundeberg, Bertil Hamberger, Peter Nilsson, Martin Bäckdahl.   

Abstract

BACKGROUND: Distinguishing between adrenocortical adenomas and carcinomas is often difficult. Our aim was to investigate the differences in transcriptional profiles between benign and malignant adrenocortical neoplasms using complementary DNA microarray techniques.
METHODS: We studied 7 patients with adrenocortical carcinomas and 13 with adenomas. Histopathology was reviewed in all patients; clinical follow-up was at least 1 year. Hybridizations were performed in duplicate against RNA reference. Expression levels were analyzed in the R environment for statistical computing with the use of aroma, limma, statistics, and class packages.
RESULTS: Transcriptional profiles were homogeneous among adenomas, while carcinomas were much more heterogeneous. Hierarchical clustering and self-organizing maps could separate clearly carcinomas from adenomas. Among genes that were most significantly upregulated in carcinomas were 2 ubiquitin-related genes (USP4 and UFD1L) and several insulinlike growth factor-related genes (IGF2, IGF2R, IGFBP3 and IGFBP6). Among genes that were most significantly downregulated in carcinomas were a cytokine gene (CXCL10), several genes related to cell metabolism (RARRES2, ALDH1A1, CYBRD1 and GSTA4), and the cadherin 2 gene (CDH2).
CONCLUSIONS: Through the use of cDNA arrays, adrenocortical adenomas and carcinomas appear to be clearly distinguishable on the basis of their specific molecular signature. The biologic importance of the up- and downregulated genes is yet to be determined.

Entities:  

Mesh:

Year:  2005        PMID: 16360395     DOI: 10.1016/j.surg.2005.09.031

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  48 in total

Review 1.  The molecular genetics of adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Gary D Hammer
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

2.  Proteome of human colon cancer stem cells: a comparative analysis.

Authors:  Jian Zou; Xiao-Feng Yu; Zhi-Jun Bao; Jie Dong
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

3.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

4.  Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin.

Authors:  Joanne H Heaton; Michelle A Wood; Alex C Kim; Lorena O Lima; Ferdous M Barlaskar; Madson Q Almeida; Maria C B V Fragoso; Rork Kuick; Antonio M Lerario; Derek P Simon; Ibere C Soares; Elisabeth Starnes; Dafydd G Thomas; Ana C Latronico; Thomas J Giordano; Gary D Hammer
Journal:  Am J Pathol       Date:  2012-07-15       Impact factor: 4.307

5.  Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling.

Authors:  Thomas J Giordano; Rork Kuick; Tobias Else; Paul G Gauger; Michelle Vinco; Juliane Bauersfeld; Donita Sanders; Dafydd G Thomas; Gerard Doherty; Gary Hammer
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

6.  TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.

Authors:  Meenu Jain; Lisa Zhang; Mei He; Ya-Qin Zhang; Min Shen; Electron Kebebew
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678

7.  USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity.

Authors:  James F Burrows; Alyson A Kelvin; Cheryl McFarlane; Roberta E Burden; Michael J McGrattan; Michelle De la Vega; Ureshnie Govender; Derek J Quinn; Karim Dib; Massimo Gadina; Christopher J Scott; James A Johnston
Journal:  J Biol Chem       Date:  2009-02-02       Impact factor: 5.157

8.  Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.

Authors:  Beatrice Rubin; Daniela Regazzo; Marco Redaelli; Carla Mucignat; Marilisa Citton; Maurizio Iacobone; Carla Scaroni; Corrado Betterle; Franco Mantero; Ambrogio Fassina; Raffaele Pezzani; Marco Boscaro
Journal:  Tumour Biol       Date:  2016-07-28

9.  PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target.

Authors:  Michael J Demeure; Kathryn E Coan; Clive S Grant; Richard A Komorowski; Elizabeth Stephan; Shripad Sinari; David Mount; Kimberly J Bussey
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

10.  Gli1 maintains cell survival by up-regulating IGFBP6 and Bcl-2 through promoter regions in parallel manner in pancreatic cancer cells.

Authors:  Xuan-Fu Xu; Chuan-Yong Guo; Jun Liu; Wen-Juan Yang; Yu-Jing Xia; Ling Xu; Yong-Chun Yu; Xing-Peng Wang
Journal:  J Carcinog       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.